These new guidelines contain wide-ranging recommendations on the use of beta-blockers, sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1, and other medical therapies to treat chronic coronary disease.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Coronary Disease
June 27, 2023
In this video, surgeons demonstrate a Vouhe procedure on a patient with anomalous left coronary artery origin from the right coronary sinus.
June 6, 2023
This video showcases a successful posterior postinfarction ventricular septal defect closure parachuting two composite handmade patches through the aortic valve and the tricuspid valve—without performing a left ventriculotomy.
March 20, 2023
In this video, using a simulator, the authors show how to deal with a graft flattening and kinking at the anastomotic site—a common error in diamond-shaped sequential anastomoses.
October 13, 2022
The CSP 474 trial challenges some of the conventional knowledge around graft choice in CABG surgery, as was presented at the European Association for Cardiothoracic Surgery (EACTS) conference.
August 19, 2022
A new analysis by a team led by Dr. Mario Gaudino of Weill Cornell Medicine and NewYork-Presbyterian shows that a combination of two antiplatelets drugs can benefit patients after coronary artery bypass graft surgery but also increases the risk of potentially dangerous bleeding.
June 23, 2022
This scientific statement is a granular contribution to a major cardiovascular issue, illuminating nuances of the "generally recognized as safe" (GRAS) FDA designation. One would expect the relevant Thoracic Associations in North America and Europe to contribute to this debate.
April 14, 2022
This 10-year follow-up of the ROBY study reports on the primary end points of all-cause death and the composite of death or revascularization among 2203 patients randomized to off-pump or on-pump CABG 2002-2007. Death rates at 10 years were 34.2% for off-pump and 31.1% for on-pump. The composite end point was reached at 4.6 years for off-pump and 5
December 25, 2021
The rising burden of CAD in low- and middle-income countries like Nigeria is a result of the epidemiological transition from communicable to non- communicable diseases. The system of care for acute coronary syndrome (ACS) is evolving and constrained by a lack of prehospital emergency services, prolonged intervention times, and low patient eligibility